CEMP News Alert Cempra Inc (CEMP) 20.66 12/25/2014 03:18:35

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cempra Inc (CEMP) 20.66 $CEMP

Cempra (CEMP) Worth Watching: Stock Moves 7.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 8:25AM CST
Cempra (CEMP) was a big mover last session, with shares rising over 7% on the day.
LCI: 42.29 (+1.79), CEMP: 20.66 (+0.78)

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
at The Street - Wed Dec 17, 8:20AM CST
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
BLUE: 88.76 (+3.23), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), NBIX: 21.33 (+0.09), GILD: 91.29 (+1.84), ARWR: 6.35 (+0.07), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), CTIC: 2.36 (+0.05), CEMP: 20.66 (+0.78), BMY: 59.15 (-0.01)

Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 88.76 (+3.23), BMRN: 88.18 (+0.89), TGTX: 16.03 (+0.33), BMY: 59.15 (-0.01), MACK: 10.91 (+0.36), FMI: 23.99 (-0.10), RNA: 18.76 (+0.10), GWPH: 68.08 (+1.82), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), ICPT: 151.49 (+5.85), THLD: 2.93 (+0.01), CEMP: 20.66 (+0.78), NVS: 93.91 (+0.66)

Cempra (CEMP) Is Today's Strong On High Volume Stock
at The Street - Fri Dec 12, 9:13AM CST
Trade-Ideas LLC identified Cempra (CEMP) as a strong on high relative volume candidate
CEMP: 20.66 (+0.78)

Will Cempra (CEMP) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:20AM CST
Will Cempra (CEMP) Continue to Surge Higher?
CEMP: 20.66 (+0.78)

Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/24xkp9/communityacquired) has announced the addition of the "Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014" report to their offering. Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014" provides data on the Community-Acquired Bacterial Pneumonia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Community-Acquired Bacterial Pneumonia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Community-Acquired Bacterial Pneumonia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Actavis plc - Cempra, Inc. - Pfizer Inc. - Cempra Pharmaceuticals, Inc. - AstraZeneca PLC - Nabriva Therapeutics AG - Cubist Pharmaceuticals, Inc. - Boehringer Ingelheim Auslandsbeteiligungs GmbH - Bayer AG - Basilea Pharmaceutica AG Clinical Trial Overview of Top Institutes / Government - Yokohama Rosai Hospital - Nagasaki Evaluation Organization for Clinical Interventions - Central Japan Lung Study Group - Albany Medical Center For more information visit http://www.researchandmarkets.com/research/24...tyacquired
CBSTZ: 0.06 (+0.01), PFE: 31.42 (-0.03), AZN: 70.44 (+0.26), CEMP: 20.66 (+0.78)

Nasdaq stocks posting largest percentage increases
AP - Tue Dec 09, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OFED: 19.01 (unch), EFOI: 5.10 (+0.01), CBST: 100.29 (-0.09), AKAO: 12.76 (-0.23), CEMP: 20.66 (+0.78), PDCE: 43.46 (-1.39), MTEX: 28.96 (unch), OTIC: 32.26 (+0.65)

Analysts say two biotech firms may be targets after Merck-Cubist deal
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 12:20PM CST

AKAO: 12.76 (-0.23), CEMP: 20.66 (+0.78)

Cempra (CEMP) in Focus: Stock Rises 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 7:37AM CST
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares rise more than 11% on the day.
LCI: 42.29 (+1.79), CEMP: 20.66 (+0.78), IG: 9.11 (-0.01), BIOD: 1.36 (-0.04)

Can Cempra (CEMP) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 7:52AM CST
Cempra has been witnessing a nice streak of beating earnings estimates. In fact, the company currently has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming beat
CEMP: 20.66 (+0.78)

Cempra to Participate in Upcoming Investor Events in December
GlobeNewswire - Wed Dec 03, 3:10PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in two upcoming investor events in December. Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will provide a company overview and update on its clinical development programs.
CEMP: 20.66 (+0.78)

Cempra Poised To Join Antibacterial Drug Acquisition Buzz With Upcoming Data Release
StockMatusow - at Seeking Alpha - Tue Nov 25, 7:00AM CST

TTPH: 38.86 (+0.53), CBST: 100.29 (-0.09), ROG: 80.02 (+1.50), CEMP: 20.66 (+0.78)

Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies
GlobeNewswire - Wed Nov 19, 5:00AM CST
$16.0 Million Will be Provided to Cover the Cost of the Study and Other Activities Specified in the Contract
CEMP: 20.66 (+0.78)

Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 38.86 (+0.53), JNJ: 104.59 (+0.31), BCRX: 11.83 (+0.76), NAVB: 2.00 (+0.02), CMRX: 36.80 (+0.70), SRPT: 13.88 (+0.47), NBS: 3.27 (+0.02), TKMR: 13.97 (+0.14), GSK: 42.85 (+0.11), CEMP: 20.66 (+0.78), OMER: 22.09 (+0.48)

Sucampo (SCMP) Worth Watching: Stock Moves 7.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 8:25AM CST
Sucampo Pharmaceuticals (SCMP) was a big mover last session, with shares rising over 7% on the day.
LCI: 42.29 (+1.79), SHPG: 209.29 (+0.07), SCMP: 13.75 (+0.44), CEMP: 20.66 (+0.78)

Cempra to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Nov 10, 3:11PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in two upcoming investor conferences. Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will provide a company overview and update on its clinical development programs.
CEMP: 20.66 (+0.78)

Moving Average Crossover Alert: Cempra (CEMP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:10AM CST
Moving Average Crossover Alert: Cempra (CEMP)
CEMP: 20.66 (+0.78)

Why Cempra (CEMP) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 7:31AM CST
Cempra has decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well
CEMP: 20.66 (+0.78)

Strength Seen in Cempra (CEMP): Stock Rises 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:25AM CDT
Cempra (CEMP) was a big mover last session, with shares rising over 10% on the day.
LCI: 42.29 (+1.79), ADHD: 4.00 (+0.24), CEMP: 20.66 (+0.78), IG: 9.11 (-0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 108

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 78

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 159

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 121

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 42

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading

Top 5 Most Recently Viewed Articles

Major Settlement Proposed for TD Mutual Fund Class Action Cases

Updated Category News Views 65

Understanding the TD Mutual Fund Class Action Settlement If you have ever held units of a TD Mutual Fund through a discount broker, you may be part of a significant class action settlement that has recently come to light. TD Asset Management Inc. has agreed to a settlement amounting to C$70.25 million aimed at resolving claims on behalf of individuals who have held units...

Continue Reading
The No-Nonsense Breakdown on Church & Dwight Co. Stocks

Updated Category News Views 192

Church & Dwight Co: The Lay of the Land Let’s be real. Church & Dwight Co Inc. (NYSE:CHD) is on the radar, trading at about $103.08, and it just popped a neat 1.46%. However, look a little deeper, and you see it’s been a rocky ride over the past year with a drop of 5.41%. Basically, it’s like gearing up for a race—only to find out you’re running on a rocky...

Continue Reading
Experience the Excitement of Jaialdi at Fairfield Inn & Suites

Updated Category News Views 256

Welcoming Guests to the Jaialdi Festival Fairfield Inn & Suites Boise West is thrilled to welcome visitors for the upcoming Jaialdi Festival, an extraordinary event that celebrates Basque culture and tradition. This festival is held once every five years and is expected to gather attendees from around the globe to participate in the festivities. The hotel, operated by...

Continue Reading
Viridien's Successful Senior Secured Notes Offering Explained

Updated Category News Views 137

Success in Senior Secured Notes Offering Today marked a significant achievement for Viridien S.A. as the company announced the successful pricing of its offering of US$450 million 10% senior secured notes and €475 million 8.5% senior secured notes, both maturing in 2030. This offering signals a strong confidence in Viridien's financial strategy and operational...

Continue Reading
Legal Insights: Investors of Ready Capital Corporation (RC) Act Now

Updated Category News Views 133

Understanding the Situation with Ready Capital Corporation (RC) As an investor in Ready Capital Corporation, it's essential to stay informed about recent developments regarding the company, especially if you've faced any financial losses. Currently, there's an important deadline approaching that could affect shareholders significantly. Key Dates and Details for Investors...

Continue Reading